Trials / Conditions / Childhood Acute Promyelocytic Leukemia (M3)

Childhood Acute Promyelocytic Leukemia (M3)

7 registered clinical trials studyying Childhood Acute Promyelocytic Leukemia (M3).

Status	Trial	Sponsor	Phase
Completed	Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia NCT01146223	Children's Oncology Group	—
Completed	Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia NCT00077467	National Cancer Institute (NCI)	Phase 1
Terminated	Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leuk NCT00042796	National Cancer Institute (NCI)	Phase 1
Completed	Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin W NCT00003934	National Cancer Institute (NCI)	Phase 3
Completed	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371	Case Comprehensive Cancer Center	Phase 2
Approved For Marketing	Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyel NCT01869803	Wake Forest University Health Sciences	—